Orphazyme Stock Today

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;padding-top: 25px;;'>OR</div>
Orphazyme is trading at 98.40 as of the 25th of May 2020, which is -0.61 percent decrease since the beginning of the trading day. The stock's open price was 99.0. Equity ratings for Orphazyme AS are calculated daily based on the scoring framework. The performance scores are derived for the period starting the 25th of February 2020 and ending today, the 25th of May 2020. Click here to learn more.
Analyze Filter   Check how we calculate scores

Orphazyme Profile

Orphazyme AS, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company was founded in 2009 and is headquartered in Copenhagen, Denmark. Orphazyme is traded on Copenhagen Stock Exchange in Denmark. more on Orphazyme
Legal NameOrphazyme AS
CEOAnders HinsbyView All
Thematic Classification
Currently Active Investing Idea
View All
Macroaxis Advice
Macroaxis buy hold or sell recommendation provided in the context of your current investment horizon and risk tolerance.
Horizon: 30 days (very short)Advice
Orphazyme AS (ORPHA) is traded on Copenhagen Stock Exchange in Denmark and employs 86 people. The company currently falls under 'Mid-Cap' category with current market capitalization of 2.63 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Orphazyme's market, we take the total number of it shares issued and multiply it by the Orphazyme's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Orphazyme AS operates under Healthcare sector and is part of Biotechnology industry. The entity has 27.04 M outstanding shares. The company has accumulated about 123.59 M in cash with (326.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.57.
Check Orphazyme Probability Of Bankruptcy

Orphazyme Stock Price Odds Analysis

Odds Down 98.4HorizonTargetOdds Up 98.4
39.24%30 days
Based on normal probability distribution, the odds of Orphazyme to move above current price in 30 days from now is about 60.64 (This Orphazyme AS probability density function shows the probability of Orphazyme Stock to fall within a particular range of prices over 30 days) .

Orphazyme AS Risk Profiles

Orphazyme Stock Against Markets

View Currently Related Equities

Orphazyme Corporate Directors

Please check Your Equity Center. Please also try Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page